Acceleron and its global partner, Bristol Myers Squibb—the industry leader in hematology—recently launched REBLOZYL® (luspatercept-aamt). The product is approved in two indications in the United States, Canada, and the European Union.
Discovered by Acceleron, luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent, which is also being developed in additional patient segments in both diseases, as well as in myelofibrosis and other possible indications. All of these serious blood disorders are marked by a late-stage defect in the maturation of red blood cells, and this defect results in chronic anemia that can affect quality of life and negatively impact a patient’s physical, social, and emotional well-being.
Acceleron is also collaborating with Adimab, an innovator in antibody discovery and optimization, in addition to Fulcrum Therapeutics, a biotech with expertise in identifying drug targets based on modulation of genetic pathways associated with disease. Adimab is working to identify fully human antibodies that Acceleron may develop and commercialize, the research for which we are funding, with the option to exclusively license newly discovered antibodies. In our agreement with Fulcrum, we will have access to their unique, proprietary product engine and target identification platform with the potential to identify small molecules that control the expression of genes known to impact specific pathways associated with a pulmonary disease of interest.